Invega Hafyera offers patients the fewest doses per year. Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
PPH is associated with almost 20 per cent of maternal mortality in India
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
The Covid-19 pandemic has exposed the divide that exists between rich and developing nations and to address these challenges the World Health Organisation (WHO), has compiled a list of innovative health technologies that aim to bridge the gap
Aashka Hospitals has entered into a non-binding agreement for its proposed tie-up with Vaidehi—Backbone hospital, Rajkot
The lab has been developed to aid surgeons to overcome the challenging learning curve to obtain laparoscopic expertise
Acetaminophen extended-release tablets 650 mg is bioequivalent of the reference listed drug Tylenol
The facility has the capacity to produce one crore doses per day
This is Enzene Biosciences third biosimilar to be approved
Subscribe To Our Newsletter & Stay Updated
